RO7759065 + atezolizumab

RO7759065 + atezolizumab is an investigational combination consisting of RO7759065, a novel agent whose precise mechanism of action and target have not yet been disclosed in public sources, and atezolizumab, a monoclonal antibody that binds to the programmed cell death ligand 1 (PD-L1) and blocks its interaction with receptors PD-1 and B7.1, thereby releasing the inhibition of immune responses against tumors. The combination is being evaluated for safety, pharmacokinetics, immunogenicity, and anti-tumor activity in patients with locally advanced or metastatic solid tumors. The trial is sponsored and developed by Genentech and Roche, and is currently at the first-in-human phase (Phase Ia/Ib). The combination seeks to leverage immune checkpoint blockade (via atezolizumab) alongside the novel activity of RO7759065, which may provide synergistic or additive antineoplastic effects, but the full role of RO7759065 is not publicly characterized[1][3][5][7][8][9].

Other names

Tecentriq